Therapie最新文献

{"title":"Psychoactive substance intoxication leading to general hospital admission in young and middle-aged people during and after the first lockdown","authors":"","doi":"10.1016/j.therap.2023.10.017","DOIUrl":"10.1016/j.therap.2023.10.017","url":null,"abstract":"<div><h3>Introduction</h3><p>Incidence of hospitalisations related to psychoactive substance (H-PS) intoxication has been strongly decreased during the coronavirus disease 2019 (COVID-19) pandemic especially in young adult and French region of Nouvelle-Aquitaine was mostly concerned. This study aimed to describe (i) the incidence of H-PS in Bordeaux teaching hospital during and after the first 2020 lockdown in adults aged 18–29 years or 30+ then (ii) their characteristics specifically associated with the pandemic period by comparing 2020 with 2017–2019 baseline period.</p></div><div><h3>Material and methods</h3><p><span><span>This historical cohort study was conducted in adults admitted to the Bordeaux teaching hospital with main or associated diagnosis codes of intoxication with </span>benzodiazepine<span>, methadone, buprenorphine, </span></span>codeine, morphine, heroin, cocaine, ecstasy and alcohol. Data were collected locally through the discharge database. Incidence and characteristics of H-PS were described according to patients’ age, in 2020 before (01/01–16/03), during (17/03–10/05), and after the first lockdown (11/05–31/07).</p></div><div><h3>Results</h3><p>Among the 5,824 stays included over the study period, PS most involved were alcohol and benzodiazepines. Compared to baseline, the decrease in H-PS's incidence was more important in young adults (−40%; n_baseline <!-->=<!--> <!-->450) in comparison to those aged 30+ (−18%; n_baseline <!-->=<!--> <!-->1,101) during the pandemic period, especially during the lockdown compared to 2017 (−59%; n₂₀₁₇ <!-->=<!--> <!-->145 vs. −35%; n₂₀₁₇ <!-->=<!--> <!-->166) with far decrease in alcohol and ecstasy intoxications. Seriousness of hospitalisation indications was increased regardless of age during the pandemic. Particularly in young adults, the proportion of suicides attempts increased during lockdown compared to the baseline period (almost 50% vs. 29%) and the period after lockdown was associated with 1.7 more-time road accident increased and 3 more-time fights compared with pre-lockdown period.</p></div><div><h3>Discussion/conclusion</h3><p>The period following lockdown should be considered at risk H-PS due to accident. Recreational use of alcohol and ecstasy could be a target for minimize serious consequences associated to PS use in young adult.</p></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138462809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Certolizumab-induced optic neuritis in a patient with spondyloarthritis: A case report and review of the literature","authors":"","doi":"10.1016/j.therap.2023.11.006","DOIUrl":"10.1016/j.therap.2023.11.006","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetic drug-drug interactions between Paxlovid® (nirmatrelvir/ritonavir) and CFTR modulators for cystic fibrosis","authors":"","doi":"10.1016/j.therap.2023.09.001","DOIUrl":"10.1016/j.therap.2023.09.001","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41161610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are clinical data from spontaneous pharmacovigilance reports transmitted via the Ministry of Health's web portal sufficient to generate a signal without further documentation?","authors":"","doi":"10.1016/j.therap.2023.10.006","DOIUrl":"10.1016/j.therap.2023.10.006","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92156835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous adverse effects of antiepileptic drugs","authors":"","doi":"10.1016/j.therap.2023.09.005","DOIUrl":"10.1016/j.therap.2023.09.005","url":null,"abstract":"<div><p><span><span>Antiepileptic drugs (AED) are widely used in therapy. They are mainly indicated in the </span>treatment of epilepsy<span> and some psychiatric pathologies as well as for their analgesic<span> action. Their cutaneous adverse effects<span> (CAE) are common, often mild but sometimes serious. The aim of this work was to study the epidemiological and clinical features<span> of CAE occurring in adults and elderly patients (aged over 20 years-old) and to identify the most implicated AED. We conducted a descriptive retrospective study over a period of five years from January 2017 to December 2022 about CAE of AED in adults and elderly patients notified to The National Center Chalbi Belkahia of Pharmacovigilance (Tunis,Tunisia). All cases were analyzed according to the updates French methods of imputability. We collected 71 cases of patients aged over 20 years old who presented CAE to AED. The age ranged from 20 to 79 years (mean age</span></span></span></span></span> <!-->=<!--> <span>44.8 years). The sex ratio F/M was 0.7. AED were indicated for neurological pathology<span><span><span><span> in 70.5% of cases, for psychiatric pathology in 15.9% of cases and for their analgesic action in 12.9% of cases. Epilepsy was the first indication (51.1% of cases). The most notified CAE in our study were drug reaction with </span>eosinophilia and systemic symptoms (DRESS syndrome; 34% of cases), </span>maculopapular exanthema<span><span><span> (MPE; 26% of cases), erythematous rash (8% of cases) and photosensitivity in 5% of cases. Severe cutaneous adverse reactions were accounted for 37% of all CAE. The most implicated AED were </span>carbamazepine (52%), </span>phenobarbital (24%) and </span></span>lamotrigine (18%). However, further study with a larger number of patients and in collaboration with prescribing physicians are needed to better clarify features of CAE associated with AED intake and specify the risk factors, specific to our Tunisian population.</span></span></p></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49682634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute generalized exanthematous pustulosis: Analysis of cases managed in a Tunisian tertiary hospital","authors":"","doi":"10.1016/j.therap.2023.11.011","DOIUrl":"10.1016/j.therap.2023.11.011","url":null,"abstract":"<div><p><span><span>Acute generalized exanthematous pustulosis<span> (AGEP) is a severe and life-threatening cutaneous adverse reaction. Drug-induced AGEP is mainly related to antibiotics. More recently, AGEP following </span></span>spider bites<span> has been increasingly described. Treatment includes withdrawal of the offending drug and supportive care. In Tunisia, data concerning severe cutaneous adverse reactions (SCARs) in general and especially AGEP is lacking. Herein, we conducted a retrospective study to investigate the epidemiological, clinical characteristics and etiologies of AGEP referred to the Dermatology department. Our study included 32 cases of AGEP. AGEP cases occurred in overall 8.9% of all SCARs referred to the department during the same period study. The majority were females (24 women and 7 men). The median age of the patients was 33 years. A history of psoriasis<span> was reported in 16.1% of patients. All patients presented with an extensive erythematous rash with pinhead pustules. Neutrophil hyperleukocytosis (greater than 7000/mm</span></span></span>³<span>) was noted in 17 patients (63% of cases). It was associated with hypereosinophilia exceeding 500 elements/mm</span>³ in 8 cases (29.6%). Drug-induced AGEP was reported in 53% of cases. Antibiotics were implicated in the majority of cases. Delay in onset ranged from 15<!--> <span>hours to 7 days, with an average of 2.8 days. A non-drug-induced etiology was considered if the pharmacological investigation was negative, or if a clear non-drug trigger was found. It was retained in ten cases (48.4% of all observations). Spider bites were revealed in 8 cases. AGEP represents a severe, usually drug-related skin reaction. It is classified as a type IVd reaction mediating T cell-related sterile neutrophilic inflammatory response. It typically occurs within 24–48 h of ingestion of the offending drug. Antibiotics are the most common drug family to cause AGEP. Spider bites were involved in 25.8% of cases in our study, as important as antibiotic-induced AGEP. Analysis of the particularities of AGEP according to etiology, whether drug-induced or not, revealed the presence of an initial escarotic lesion (</span><em>P</em> <!-->=<!--> <!-->0.01) and the finding of blood hypereosinophilia (<em>P</em> <!-->=<!--> <span>0.014) in the non-drug AGEP group were the distinguishing features. Blood hyperesoniophilia, more frequent in the non-drug AGEP group, suggests a pathophysiology probably different from that of the drug AGEP group. Clinicians should be aware of both etiologies. Our study focuses on the importance of AGEP associated with spider bite as a potential triggering factor in Tunisia.</span></p></div>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139032586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolated conjugated hyperbilirubinemia with rifampicin and cross-reaction with rifabutin: A drug-endogenous substance interaction case report","authors":"","doi":"10.1016/j.therap.2023.09.006","DOIUrl":"10.1016/j.therap.2023.09.006","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49682635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation d’une version française de l’outil AT-HARM10 pour la détection des hospitalisations liées au médicament","authors":"","doi":"10.1016/j.therap.2023.10.015","DOIUrl":"10.1016/j.therap.2023.10.015","url":null,"abstract":"<div><p>Les admissions des personnes âgées pour cause d’évènement iatrogène médicamenteux sont fréquentes à l’hôpital. Cependant, il n’existe pas à ce jour de méthode validée en langue française pour les identifier. L’objectif de ce travail a été de valider la version francophone de l’outil AT-HARM10 pour une utilisation à l’admission des patients dans nos structures de soins. Il se présente sous la forme de 10 questions fermées. Une réponse positive à l’une des 3 premières questions met en évidence une admission non liée au médicament. Une réponse positive à l’un des 7 items suivants définit une cause iatrogène probablement en lien avec l’hospitalisation. Nous avons effectué une validation sémantique et linguistique par validation croisée sous forme d’allers-retours entre experts. Pour valider cliniquement le questionnaire, nous avons réalisé une étude rétrospective sur les dossiers de patients de plus de 65 ans admis en unité d’hospitalisation de courte durée (UHCD) et en chirurgie orthopédique et traumatologie au sein de deux établissements hospitaliers. La fiabilité inter-opérateur était élevée (taux d’accord initial entre évaluateurs<!--> <!-->=<!--> <!-->87 %, coefficient kappa de Cohen<!--> <!-->=<!--> <!-->0,75). Nous avons analysé 266 dossiers de 166 patients admis en UHCD (âge moyen 86,0<!--> <!-->±<!--> <!-->5,7 ans; sexe ratio 0,66; nombre moyen de médicaments prescrits 7,7<!--> <!-->±<!--> <!-->3,8) et 100 patients admis dans les services de chirurgie orthopédique et traumatologie (âge moyen 85,2<!--> <!-->±<!--> <!-->6,1 ans; sexe ratio 0,43 ; nombre moyen de médicaments prescrits 6,4<!--> <!-->±<!--> <!-->3,6). Nous avons identifié 55 % d’admissions en lien probable avec le médicament en UHCD et 76 % dans les unités d’orthopédie (<em>P</em> <!-->&lt;<!--> <!-->0,05). L’item du questionnaire le plus représenté était P5 dans les deux groupes. L’outil AT-HARM10 validé est désormais intégré à nos pratiques de pharmacie clinique et des bilans de médication sont proposés en priorité aux patients admis pour motif iatrogène.</p></div><div><p>Admissions of the elderly related to medication errors are frequent in hospital, more than half would be avoidable, but there is currently no validated method in French to identify them. The objective of this work was to validate the French version of the AT-HARM10 tool in order to use it for patients admitted in our healthcare facilities. The tool has 10 questions. A positive response to any of the first 3 questions identify admissions that are unlikely to be drug-related. A positive response to one of the following 7 questions identify possible medication-related admissions. For semantic and linguistic validation, we performed cross-validation with forward-backward translation. To clinically validate the method, we conducted a retrospective study including patients over 65 admitted to short-stay units (UHCD) and to orthopedic surgery units in two French hospitals. Two hundred and sixty-six (266) pati","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138441310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"État des lieux de la mise en place en France des entretiens pharmaceutiques en officine : analyse des réponses issues d’un questionnaire","authors":"","doi":"10.1016/j.therap.2023.11.010","DOIUrl":"10.1016/j.therap.2023.11.010","url":null,"abstract":"<div><h3>Objectif</h3><p>Évaluer le développement des entretiens pharmaceutiques en officine en France afin de comprendre l’organisation mise en œuvre, les éventuelles limites et l’élargissement des pathologies éligibles.</p></div><div><h3>Méthode</h3><p>Un questionnaire dématérialisé a été élaboré puis diffusé entre novembre 2022 et février 2023 auprès des pharmaciens et des étudiants en pharmacie de France (Métropole et Outre-Mer) au travers d’un lien vers un Google Form.</p></div><div><h3>Résultats</h3><p>Quatre-vingt-quatorze pharmaciens provenant de 8 régions différentes de la France ont répondu à l’enquête. Les 94 réponses récoltées ont permis de visualiser que 56 % des pharmaciens d’officine pratiquaient les entretiens pharmaceutiques. Parmi les pharmaciens qui pratiquaient les entretiens les titulaires des officines pratiquaient significativement plus d’entretiens que les autres statuts au sein de l’officine (67 % vs 38 % ; <em>p</em> <!-->=<!--> <!-->0,014). Aucun autre facteur comme la taille de l’officine, ou la zone géographique d’exercice ne montraient d’impact significatif sur la réalisation ou non des entretiens pharmaceutiques. Ces entretiens sont souvent réalisés sur demande des patients, 89 % de ces entretiens sont accompagnés de documents à l’attention du patient. Pour les pharmaciens ne réalisant pas les entretiens, le temps, le personnel et la rémunération sont les 3 principaux éléments bloquant retrouvés autant dans les variables quantitatives que dans le verbatim. Que les pharmaciens pratiquent ou non l’entretien pharmaceutique, cette activité reçoit 87 % d’avis favorable parmi les 94 répondants de même 84 % d’entre eux voudraient inclure plus de thèmes de pathologies chroniques.</p></div><div><h3>Conclusion</h3><p>L’enquête montre une approbation de cette activité d’entretiens pharmaceutiques par les pharmaciens d’officine mais cette étude met en évidence des freins logistiques évidents liés à un manque de moyen. Ainsi même parmi les pharmaciens qui réalisent les entretiens pharmaceutiques cette activité reste réalisée assez peu en routine et souvent par le pharmacien titulaire qui prend sur lui la responsabilité de porter cette activité.</p></div><div><h3>Objective</h3><p>To evaluate the development of pharmaceutical interviews in pharmacies in France, in order to understand the organization implemented, any limitations and the expansion of eligible pathologies.</p></div><div><h3>Method</h3><p>A dematerialized questionnaire was designed and distributed between November 2022 and February 2023 to pharmacists and pharmacy students in France (mainland and overseas) via a link to a Google Form.</p></div><div><h3>Results</h3><p>Ninety-four pharmacists from 8 different regions of France responded to the survey. The 94 responses showed that 56% of pharmacists practiced pharmaceutical interviews. Among pharmacists who practiced interviews, pharmacy owners practiced significantly more interviews than other statuses within the pharm","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Terbinafine induced bullous pemphigoid","authors":"","doi":"10.1016/j.therap.2023.12.005","DOIUrl":"10.1016/j.therap.2023.12.005","url":null,"abstract":"","PeriodicalId":23147,"journal":{"name":"Therapie","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139633225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}